Intelligent anti-aging skin care based on independent research     
Lose wrinkles, keep your bank account!     
 
Skin Care 101
Skin Care Basics
Skin Protection
Skin Biology
Biology of Aging
Ingredient Guide
Skin & Nutrition
Skin Conditions
 
Anti-Aging Treatments
Topical Actives
Wrinkle Fillers
Noninvasive
Invasive
 
Skin Care Smarts
Smart Choices
Best Practices
Find Good Skin Doc
Quick Tips
Freebie Finder
 
Reviews & Research
Product Reviews
Provider Reviews
Skin Care Research
Clinical Trials
 
How-To Infopacks
Skin Rejuvenation
DIY Skin Care
Skin & Nutrition
Eye Skin Care
Longevity In a Pill
 
Community & Misc
Forums
Polls & Surveys
News and Updates
Search
 
   
You are here: Skin Care Research >

Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females.

Author: Carruthers A, Carruthers J, Said S

Author affiliation: University of British Columbia, Vancouver, British Columbia, Canada. alastair@carruthers.net

Publication date & source: 2005.04, Dermatol Surg., 31(4):414-22

Publication type: Clinical Trial; Randomized Controlled Trial

OBJECTIVE: To compare the efficacy, safety, and duration of effect of four doses of botulinum toxin type A in the treatment of glabellar rhytids in females. DESIGN: Double-blind, randomized, parallel-group, dose-ranging trial followed by an open-label extension. SETTING: Private dermatologic clinic. SUBJECTS: Eighty female subjects with moderate to severe wrinkles at maximum frown entered the study. The first 40 subjects completing the double-blind phase entered the open-label extension. INTERVENTION: Random administration of 10, 20, 30, or 40 U botulinum toxin type A in divided doses. Open-label trial: 30 U botulinum toxin type A at the same sites in divided doses. MAIN OUTCOME MEASUREMENTS: Trained observer and subject assessments of wrinkle severity at maximum frown and repose using the Facial Wrinkle Scale (0 = none to 3 = severe), subject satisfaction, and adverse events. Follow-up monthly for up to 1 year postinjection. RESULTS: Relapse rates and responder rates revealed benefits lasting 3 to 6 months or longer. Objectively, 10 U of botulinum toxin type A was significantly less effective than 20, 30, or 40 U. The relapse rate at 4 months was significantly higher in the 10 U group (83%) versus 40, 30, or 20 U (28%, 30%, and 33%, respectively). Subject satisfaction was high in all groups. Duration of effect and response rates were sustained during the open-label extension. Adverse effects were mild and infrequent. CONCLUSION: Twenty to 40 U botulinum toxin type A doses were significantly more effective at reducing glabellar lines than 10 U. Most subjects experienced benefits for 3 to 4 months; some subjects demonstrated effect for up to 12 months.



Indexes of Skin Care Research Abstracts
by Subject Category Most Recent


Google
 
Web SmartSkinCare.com

Home | About Us | Contact Us | Ask a Question | Resources

Copyright © 1999-2009 by Dr. G. Todorov / SmartSkinCare.com
Site Disclaimer | Copyright Certification

   
-- advertisements --